ImmunoGen Reports Recent Progress and 2019 Financial Results
ImmunoGen, Inc. (IMGN)
Last immunogen, inc. earnings: 5/1 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.immunogen.com/investor-relations
Company Research
Source: Business Wire
Accelerated Approval Pathway Defined for Mirvetuximab Soravtansine in Ovarian Cancer; Pivotal SORAYA Trial Expected to Enroll First Patient in Q1 2020 Phase 3 Confirmatory MIRASOL Trial for Mirvetuximab Enrolling PatientsUpdated IMGN632 AML and BPDCN Monotherapy Data Presented at ASH$97.6 Million Net Proceeds from Public Offering Extends Cash Runway to Second Half of 2022Conference Call to be Held at 8:00 a.m. ET Today WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter and year ended December 31, 2019.“Following the results of FORWARD I, we moved decisively to restructure the business to reduce our costs, prioritized our portfolio to focus on our most promising programs, and worked constructively with FDA to define an accelerated path to approval for mirvetuximab,” said Mark Enye
Show less
Read more
Impact Snapshot
Event Time:
IMGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMGN alerts
High impacting ImmunoGen, Inc. news events
Weekly update
A roundup of the hottest topics
IMGN
News
- Is ImmunoGen (IMGN) Outperforming Other Medical Stocks This Year? [Yahoo! Finance]Yahoo! Finance
- Immunogen Inc SVP & CHIEF BUSINESS OFFICER Stacy Coen Sells 4,583 Shares [Yahoo! Finance]Yahoo! Finance
- ImmunoGen, Inc. (NASDAQ: IMGN) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- AbbVie Sees Signs of Post-Humira Growth in Positive 2024 Outlook [BNN Bloomberg (Canada)]BNN Bloomberg
- ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
IMGN
Earnings
- 11/2/23 - Beat
IMGN
Sec Filings
- 2/12/24 - Form 4
- 2/12/24 - Form 4
- 2/12/24 - Form 4
- IMGN's page on the SEC website